Coloplast interim CEO Lars Rasmussen has today informed the Coloplast Board of Directors that he will not stand for re-election as board member at the upcoming annual general meeting on December 4, ...

Based in Denmark, Coloplast is a leader in global ostomy and continence care. The firm has made inroads into the concentrated urology and fragmented woundcare markets, but it remains a peripheral ...

Coloplast's growth momentum and margins are declining, with recent operational missteps and weak demand, especially in China, weighing on results. Despite a strong market position and defensive ...

Coloplast is a global leader in specialized intimate healthcare, with strong innovation, high margins, and a defensible moat in core segments. Despite a 20% share price drop, I see upside potential, ...

On Friday, RBC Capital Markets adjusted its stance on Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY), downgrading the company’s stock rating from Outperform to Sector Perform and reducing the price ...

(Bloomberg) — Coloplast A/S fired its chief executive officer to restore investor confidence after the medical equipment maker failed to deliver sufficient shareholder returns. That’s according to ...

On Monday, Deutsche Bank analysts adjusted their stance on Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY), downgrading the medical device company’s stock rating from Buy to Hold. Accompanying this ...

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy ...

Group organic growth was 7% in H1. The EBIT margin before special items was 27%. Organic growth rates by business area: Ostomy Care 6%, Continence Care 7%, Voice and Respiratory Care 9%, Advanced ...

On Monday, RBC Capital Markets analyst Jack Reynolds-Clark revised the rating for Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY), elevating it from Sector Perform to Outperform. Accompanying this ...

In relation to the launch of Coloplast's new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue CAGR of 7-8% until FY 2029/30, growth in absolute EBIT* in ...